Equities analysts expect PRA Health Sciences (NASDAQ:PRAH) to report earnings of $0.84 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for PRA Health Sciences’ earnings, with the highest EPS estimate coming in at $0.85 and the lowest estimate coming in at $0.83. PRA Health Sciences reported earnings of $0.62 per share in the same quarter last year, which would indicate a positive year over year growth rate of 35.5%. The company is expected to report its next earnings results after the market closes on Wednesday, April 25th.

According to Zacks, analysts expect that PRA Health Sciences will report full-year earnings of $4.12 per share for the current financial year, with EPS estimates ranging from $4.05 to $4.15. For the next year, analysts forecast that the company will report earnings of $4.85 per share, with EPS estimates ranging from $4.65 to $5.07. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover PRA Health Sciences.

How to Become a New Pot Stock Millionaire

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.02. PRA Health Sciences had a net margin of 3.85% and a return on equity of 22.77%. The business had revenue of $568.80 million for the quarter, compared to analyst estimates of $543.78 million. During the same period in the previous year, the business earned $0.71 EPS. The firm’s revenue was up 37.5% on a year-over-year basis.

Several equities analysts recently issued reports on the stock. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 13th. Zacks Investment Research downgraded shares of PRA Health Sciences from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Credit Suisse Group reissued an “outperform” rating and set a $104.00 price target (up from $101.00) on shares of PRA Health Sciences in a report on Thursday, February 22nd. KeyCorp reissued a “buy” rating and set a $100.00 price target on shares of PRA Health Sciences in a report on Wednesday, January 31st. Finally, Mizuho downgraded shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target for the company. in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $95.67.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of PRA Health Sciences by 52.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,647 shares of the medical research company’s stock worth $150,000 after acquiring an additional 567 shares during the last quarter. American International Group Inc. raised its stake in shares of PRA Health Sciences by 2.1% in the fourth quarter. American International Group Inc. now owns 33,402 shares of the medical research company’s stock worth $3,042,000 after acquiring an additional 683 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of PRA Health Sciences by 1.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 37,921 shares of the medical research company’s stock worth $3,454,000 after acquiring an additional 713 shares during the last quarter. First Bank & Trust raised its stake in shares of PRA Health Sciences by 30.0% in the fourth quarter. First Bank & Trust now owns 3,259 shares of the medical research company’s stock worth $297,000 after acquiring an additional 752 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of PRA Health Sciences by 23.5% in the third quarter. Ameritas Investment Partners Inc. now owns 4,204 shares of the medical research company’s stock worth $325,000 after acquiring an additional 800 shares during the last quarter. 99.22% of the stock is owned by institutional investors.

Shares of PRAH stock opened at $87.98 on Thursday. PRA Health Sciences has a 12-month low of $61.93 and a 12-month high of $95.90. The stock has a market cap of $5,549.81, a P/E ratio of 27.49, a PEG ratio of 1.39 and a beta of 0.49. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.31.

WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/04/17/0-84-earnings-per-share-expected-for-pra-health-sciences-prah-this-quarter.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.